R Pedragosa

Journal Article Safety and effectiveness of ustekinumab and antitumour necrosis factor therapy in patients with psoriasis and chronic viral hepatitis B or C: a retrospective, multicentre study in a clinical setting Get access R. Navarro, R. Navarro Department of Dermatology, Hospital Universitario de la Princesa, Madrid, Spain Raquel Navarro. E‐mail: nat_eraa@hotmail.com Search for other works by this author on: Oxford Academic Google Scholar E. Vilarrasa, E. Vilarrasa Department of Dermatology, Hospital de la Santa Creu i Sant Pau, Universitat Autónoma de Barcelona, Barcelona, Spain Search for other works by this author on: Oxford Academic Google Scholar P. Herranz, P. Herranz Department of Dermatology, Hospital Universitario la Paz, Madrid, Spain Search for other works by this author on: Oxford Academic Google Scholar L. Puig, L. Puig Department of Dermatology, Hospital de la Santa Creu i Sant Pau, Universitat Autónoma de Barcelona, Barcelona, Spain Search for other works by this author on: Oxford Academic Google Scholar X. Bordas, X. Bordas Department of Dermatology, Hospital de Bellvitge, Barcelona, Spain Search for other works by this author on: Oxford Academic Google Scholar J.M. Carrascosa, J.M. Carrascosa Department of Dermatology, Hospital Universitari Germans Trias i Pujol, Badalona, Spain Search for other works by this author on: Oxford Academic Google Scholar R. Taberner, R. Taberner Department of Dermatology, Hospital Son Llátzer, Mallorca, Spain Search for other works by this author on: Oxford Academic Google Scholar M. Ferrán, M. Ferrán Department of Dermatology, Hospital del Mar, Barcelona, Spain Search for other works by this author on: Oxford Academic Google Scholar M. García‐Bustinduy, M. García‐Bustinduy Department of Dermatology, Hospital Universitario de Canarias, La Laguna, Spain Search for other works by this author on: Oxford Academic Google Scholar A. Romero‐Maté, A. Romero‐Maté Department of Dermatology, Hospital de Fuenlabrada, Madrid, Spain Search for other works by this author on: Oxford Academic Google Scholar ... Show more R. Pedragosa, R. Pedragosa Department of Dermatology, Hospital Plató, Barcelona, Spain Search for other works by this author on: Oxford Academic Google Scholar A. García‐Diez, A. García‐Diez Department of Dermatology, Hospital Universitario de la Princesa, Madrid, Spain Search for other works by this author on: Oxford Academic Google Scholar E. Daudén E. Daudén Department of Dermatology, Hospital Universitario de la Princesa, Madrid, Spain Search for other works by this author on: Oxford Academic Google Scholar British Journal of Dermatology, Volume 168, Issue 3, 1 March 2013, Pages 609–616, https://doi.org/10.1111/bjd.12045 Published: 01 March 2013 Article history Accepted: 07 September 2012 Published: 01 March 2013

Two patients with Hodgkin's disease developed a condition that has been termed “reactive perforating collagenosis.” In both cases, pruritus was severe and seemed to be responsible for the vigorous rubbing and scratching that caused the skin lesions. In one patient, the lesions disappeared upon remission of Hodgkin's disease. Perforating collagenosis has been described in children as a hereditary disease, and has also been described in adults with diabetes and on hemodialysis. On the basis of the changes seen in our two patients with Hodgkin's disease, we suggest that perforating collagenosis is simply a consequence of intense scratching.

All cases of MM diagnosed in 23 hospitals in Catalonia, from 2000 to 2007 were recorded and melanoma incidence calculated and adjusted for the European standard population via the direct method. The age standardised rate/100,000 inhabitants varied from 6.74 in 2000 to 8.64 in 2007 for all melanomas and from 4.79 to 5.80 for invasive MMs; the Breslow thickness was stable during the period. The increase in invasive melanoma incidence in the elderly was remarkable, the crude rate/100,000 inhabitants increasing from 11.04 (2000) to 15.49 (2007) in the 60-64 year population, while remaining more stable in the 30-34 year range, from 3.97 in 2000 to 4.55 in 2007, and with a tendency to decrease from 5.1 in 2000 to 2.5 in 2007 for the age range of 25-29 years. These lower age ranges are much more affected by immigration. Despite the large immigrant population (nearly one million immigrants arrived in Catalonia during the study period from countries with a low melanoma incidence), melanoma incidence in our region has risen considerably and this trend is likely to persist in the near future.

We report the clinical evolution of two young siblings with severe pemphigus vulgaris treated with cyclosporine for 30 and 12 months, respectively. One was resistant to treatment with high-dose corticosteroids and azathioprine. A good clinical response was achieved in both cases. No major side effects were observed. The patients have remained disease free for more than 20 months after stopping cyclosporine therapy.

Recent epidemiological studies suggest that past data where superficial spreading melanoma was by far the most common subtype of melanoma may not reflect current patterns of sun exposure or other risk factors more involved in other subtypes of melanoma as lentigo maligna (LM) or lentigo maligna melanoma (LMM).In order to measure the current situation in our country, all cases of LM and LMM diagnosed in 23 hospitals in Catalonia, from 2000 to 2007, were recorded.Although for the global period LM/LMM represented only 8.4% of cases, an increasing trend in this percentage was observed throughout the study period (from 6.9% [27 cases] in 2000 to 13.1% [94 cases] in 2007). Also, an increasing incidence of LM/LMM was observed, especially in chronically sun-exposed areas (85.5% involving the head and neck region). During the 8 years of the registry, the mean Breslow thickness of LMM remained stable. However, the increase in the number of LM (in situ) cases was significantly higher than the increase of the invasive ones.An important observation from this data is that aging of population and current sun exposure patterns could keep increasing the incidence of LM/LMM, which may become an important public healthcare problem, over the other histological subtypes. In order to establish primary or secondary preventive measures to the LM/LMM risk-population, it is imperative to highlight the importance of chronic sun damage as a melanoma risk factor, and not only sunburn, most commonly addressed in melanoma prevention campaigns.

El documento de consenso respecto al manejo del melanoma primario de la piel, que detallamos a continuación, nace de la puesta en común, aceptación, revisión y confrontación con la literatura reciente (incluyendo guías clínicas nacionales e internacionales), así como de los protocolos de diagnóstico, seguimiento y tratamiento consensuados en los diferentes centros hospitalarios de toda Cataluña y Balerares pertenencientes a la Xarxa de Centres de Melanoma de Catalunya i Balears. El objetivo principal de este documento es exponer de forma conjunta el manejo habitual del paciente con melanoma que actualmente se realiza en nuestro medio. Sin embargo, este documento no pretende, ni puede, por lo que tampoco debiera ser usado como un protocolo de obligado cumplimiento por los profesionales que atendemos a este grupo de enfermos. En este sentido, cabe mencionar que la consulta de este documento por parte del profesional no es vinculante para su acción, y en ningún caso este texto podrá ser utilizado para garantizar o buscar responsabilidades del juicio médico concreto. El grupo de dermatólogos que firman dicho documento se formó hace ahora tres años, con la intención de dar a conocer a nuestras autoridades la importancia de este complejo tumor, que en nuestro país creemos que se encuentra erróneamente infravalorada con respecto a otros tipo de cáncer. Además, fruto de las reuniones periódicas del grupo, han surgido también interesantes propuestas de colaboración en distintos proyectos de investigación epidemiológica, clínica y básica aplicada en torno al melanoma maligno en nuestra sociedad. The consensus statement on the management of primary cutaneous melanoma that we present here was based on selection, discussion, review, and comparison of recent literature (including national and international guidelines). The protocols for the diagnosis, treatment, and follow-up used in the hospital centers throughout Catalonia and the Balearic Isles belonging to the Network of Catalan and Balearic Melanoma Centers were also considered. The main objective of this statement was to present the overall management of melanoma patients typically used in our region at the present time. As such, the statement was not designed to be an obligatory protocol for health professionals caring for this group of patients, and neither can it nor should it be used for this purpose. Professionals reading the statement should not therefore consider it binding on their practice, and in no case can this text be used to guarantee or seek responsibility for a given medical opinion. The group of dermatologists who have signed this statement was created 3 years ago with the aim of making our authorities aware of the importance of this complex tumor, which, in comparison with other types of cancer, we believe does not receive sufficient attention in Spain. In addition, the regular meetings of the group have produced interesting proposals for collaboration in various epidemiological, clinical, and basic applied research projects on the subject of malignant melanoma in our society.

Letters and Corrections1 September 1986Leukocytoclastic Vasculitis After High-Dose MethotrexateM. NAVARRO, M.D., R. PEDRAGOSA, M.D., A. LAFUERZA, M.D., D. RUBIO, M.D., P. HUGUET, M.D.M. NAVARRO, M.D.Search for more papers by this author, R. PEDRAGOSA, M.D.Search for more papers by this author, A. LAFUERZA, M.D.Search for more papers by this author, D. RUBIO, M.D.Search for more papers by this author, P. HUGUET, M.D.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-105-3-471_3 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptTo the editor: Leukocytoclastic vasculitis is a rare side effect of cytostatic treatment. This lesion has been seen after treatment with busulfan, hydroxyurea, and propylthiouracil (1), but it has not been seen in association with osteogenic sarcoma. We describe the case of a patient with osteogenic sarcoma who developed a leukocytoclastic vasculitis that could be ascribed to treatment with high-dose methotrexate.A 45-year-old man developed osteogenic sarcoma in the condyle of his left femur. He was placed on a preoperative chemotherapeutic protocol using the drug schedule proposed by Rosen and colleagues (2). Briefly, this regimen consists of four weekly doses...References1. WEISS R. Hypersensitivity reaction to cancer chemotherapy. Semin Oncol. 1982;9:5-13. MedlineGoogle Scholar2. ROSENCAPARROSHUVOS GBA. Preoperative chemotherapy for osteogenic sarcoma: selection of postoperative adjuvant chemotherapy based on the response of the primary tumor to preoperative chemotherapy. Cancer. 1982;49:1221-30. CrossrefMedlineGoogle Scholar3. KAPLANWIERNIK RP. Neurotoxicity of antineoplastic drugs. Semin Oncol. 1982;9:103-30. MedlineGoogle Scholar4. CADMANLUNDBERGBERTINO EWJ. Systemic methotrexate toxicity: a pharmacological study of its occurrence after intrathecal administration in a patient with renal failure. Arch Intern Med. 1976;136:1321-2. CrossrefMedlineGoogle Scholar5. LANZKOWSKYJAYABOSESHENDELEVY PSAR. Vasculitis as a complication of high-dose methotrexate in the treatment of acute leukemia [Letter]. Am J Dis Child. 1976;130:675. MedlineGoogle Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAuthors: M. NAVARRO, M.D.; R. PEDRAGOSA, M.D.; A. LAFUERZA, M.D.; D. RUBIO, M.D.; P. HUGUET, M.D.Affiliations: Valle Hebron Hospital 08035 Barcelona Spain PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byMethotrexate-Induced Vasculitis in a Child with Systemic Onset Juvenile Idiopathic ArthritisLeukocytoclastic Vasculitis and Desensitization to High-dose Methotrexate in Primary Central Nervous System LymphomaDrug ReactionsVascular Toxicity of Antineoplastic AgentsCutaneous and Systemic Manifestations of Drug-Induced VasculitisMethotrexate-responsive chronic idiopathic urticaria: a report of two cases.Leukocytoclastic vasculitis induced by low-dose methotrexate: in vitro evidence for an immunologic mechanismCutaneous necrotizing vasculitis after low dose methotrexate therapy for rheumatoid arthritis: A possible manifestation of methotrexate hypersensitivityAcute febrile toxic reaction in patients with refractory rheumatoid arthritis who are receiving combined therapy with methotrexate and azathioprineCutaneous Lymphocytic Vasculopathy in Lymphoproliferative Disorders-A Paraneoplastic Lymphocytic Vasculitis of the SkinCutaneous drug reactionsTreatment of vasculitis.Long-term methotrexate therapy for rheumatoid arthritisDrug-induced vasculitidesRheumatic syndromes caused by antirheumatic drugsToxic Skin Reaction Restricted to Palms and Soles after High-Dose MethotrexateCUTANEOUS VASCULITIS AFTER INTERMEDIATE DOSE OF METHOTREXATE (IDMTX)Drug-Induced Rheumatic SyndromesMethotrexate in rheumatoid arthritis 1 September 1986Volume 105, Issue 3Page: 471-472KeywordsDrugsFemurLesionsMethotrexateSarcomaVasculitis ePublished: 1 December 2008 Issue Published: 1 September 1986 PDF downloadLoading ...

This consensus statement on the management of primary cutaneous melanoma that we present here was based on selection, discussion, review, and comparison of recent literature (including national and international guidelines). The protocols for the diagnosis, treatment, and follow-up used in the hospital centers throughout Catalonia and the Balearic Isles belonging to the Network of Catalan and Balearic Melanoma Centers were also considered. The main objective of this statement was to present the overall management of melanoma patients typically used in our region at the present time. As such, the statement was not designed to be an obligatory protocol for health professionals caring for this group of patients, and neither can it nor should it be used for this purpose. Professionals reading the statement should not therefore consider it binding on their practice, and in no case can this text be used to guarantee or seek responsibility for a given medical opinion. The group of dermatologists who have signed this statement was created 3 years ago with the aim of making our authorities aware of the importance of this complex tumor, which, in comparison with other types of cancer, we believe does not receive sufficient attention in Spain. In addition, the regular meetings of the group have produced interesting proposals for collaboration in various epidemiological, clinical, and basic applied research projects on the subject of malignant melanoma in our society. El documento de consenso respecto al manejo del melanoma primario de la piel, que detallamos a continuación, nace de la puesta en común, aceptación, revisión y confrontación con la literatura reciente (incluyendo guías clínicas nacionales e internacionales), así como de los protocolos de diagnóstico, seguimiento y tratamiento consensuados en los diferentes centros hospitalarios de toda Cataluña y Baleares pertenecientes a la Xarxa de Centres de Melanoma de Catalunya i Balears. El objetivo principal de este documento es exponer de forma conjunta el manejo habitual del paciente con melanoma que actualmente se realiza en nuestro medio. Sin embargo, este documento no pretende, ni puede, por lo que tampoco debiera ser usado como un protocolo de obligado cumplimiento por los profesionales que atendemos a este grupo de enfermos. En este sentido, cabe mencionar que la consulta de este documento por parte del profesional no es vinculante para su acción, y en ningún caso este texto podrá ser utilizado para garantizar o buscar responsabilidades del juicio médico concreto. El grupo de dermatólogos que firman dicho documento se formó hace ahora tres años, con la intención de dar a conocer a nuestras autoridades la importancia de este complejo tumor, que en nuestro país creemos que se encuentra erróneamente infravalorada con respecto a otros tipo de cáncer. Además, fruto de las reuniones periódicas del grupo, han surgido también interesantes propuestas de colaboración en distintos proyectos de investigación epidemiológica, clínica y básica aplicada en torno al melanoma maligno en nuestra sociedad.

International Journal of DermatologyVolume 30, Issue 9 p. 648-650 Sweet Syndrome in Chronic Myelogenous Leukemia Urbá Gonzalez-Castro M.D., Corresponding Author Urbá Gonzalez-Castro M.D. Dermatology Service and the Hematology Service, Vail d'Hebron University General Hospital, Barcelona, Spain.Address correspondence to: Urbá Gonzalez-Castro, M.D., Servei de Dermatologia, Hospital General Universitari Vall d'Hebron, Pg. Vail d'Hebron s/n, 08035 Barcelona, Spain.Search for more papers by this authorAntoni Juliá M.D., Antoni Juliá M.D. Dermatology Service and the Hematology Service, Vail d'Hebron University General Hospital, Barcelona, Spain.Search for more papers by this authorRamón Pedragosa M.D., Ramón Pedragosa M.D. Dermatology Service and the Hematology Service, Vail d'Hebron University General Hospital, Barcelona, Spain.Search for more papers by this authorJosep Bueno M.D., Josep Bueno M.D. Dermatology Service and the Hematology Service, Vail d'Hebron University General Hospital, Barcelona, Spain.Search for more papers by this authorJordi Vidal M.D., Jordi Vidal M.D. Dermatology Service and the Hematology Service, Vail d'Hebron University General Hospital, Barcelona, Spain.Search for more papers by this authorAntoni Casteils M.D., Antoni Casteils M.D. Dermatology Service and the Hematology Service, Vail d'Hebron University General Hospital, Barcelona, Spain.Search for more papers by this author Urbá Gonzalez-Castro M.D., Corresponding Author Urbá Gonzalez-Castro M.D. Dermatology Service and the Hematology Service, Vail d'Hebron University General Hospital, Barcelona, Spain.Address correspondence to: Urbá Gonzalez-Castro, M.D., Servei de Dermatologia, Hospital General Universitari Vall d'Hebron, Pg. Vail d'Hebron s/n, 08035 Barcelona, Spain.Search for more papers by this authorAntoni Juliá M.D., Antoni Juliá M.D. Dermatology Service and the Hematology Service, Vail d'Hebron University General Hospital, Barcelona, Spain.Search for more papers by this authorRamón Pedragosa M.D., Ramón Pedragosa M.D. Dermatology Service and the Hematology Service, Vail d'Hebron University General Hospital, Barcelona, Spain.Search for more papers by this authorJosep Bueno M.D., Josep Bueno M.D. Dermatology Service and the Hematology Service, Vail d'Hebron University General Hospital, Barcelona, Spain.Search for more papers by this authorJordi Vidal M.D., Jordi Vidal M.D. Dermatology Service and the Hematology Service, Vail d'Hebron University General Hospital, Barcelona, Spain.Search for more papers by this authorAntoni Casteils M.D., Antoni Casteils M.D. Dermatology Service and the Hematology Service, Vail d'Hebron University General Hospital, Barcelona, Spain.Search for more papers by this author First published: September 1991 https://doi.org/10.1111/j.1365-4362.1991.tb03492.xCitations: 13 See also pages 635, 640, 644. AboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onFacebookTwitterLinked InRedditWechat Citing Literature Volume30, Issue9September 1991Pages 648-650 RelatedInformation

<h3>To the Editor.—</h3> Pentazocine is a potent analgesic considered as a synthetic morphinelike narcotic agonist, and its abuse has led to the development of severe complications of the vascular, respiratory, and central nervous systems, which complications are more common among drug addicts using arterial or intravenous lines for injection of insoluble oral preparations.¹ By far the commonest side effects of pentazocine abuse are cutaneous.²The subcutaneous or intramuscular self-administration of parenteral preparations may lead to the development of sclerodermalike inflammatory lesions, subcutaneous abscesses, cellulitis, ulceration, muscle atrophy, and granulomas.³An isolated case of toxic epidermal necrolysis in a patient with severe renal failure has also been reported.⁴ <h3>Report of a Case.—</h3> Because of severe pain, analgesic treatment with pentazocine, aspirin, and codeine was initiated in a 65-year-old woman with a resected adenocarcinoma of the rectum and metastatic lesions in the sacral region. On the third day

We present the case of an 11-month-old baby with a burn that healed normally over a month, but subsequently developed successive crops of blisters over the scar. There were no changes in his general condition. Clinical, immunological, histological and ultrastructural studies provided a diagnosis of mechanical dermatitis produced by microtrauma. Electron microscopy studies revealed the sub-epidermal nature of the blisters and the presence of underlying fibrin deposits.

Porphyria cutanea tarda (PCT) is an unfrequent disorder in patients with acquired immunodeficiency syndrome (AIDS) due to deficiency in uroporphyrinogen decarboxilase. The more frequent cutaneous manifestations are skin fragility and hypertrichosis.A 44-years-old man with AIDS presented an intense cutaneous hyperpigmentation, preferently involving sun-exposed areas. Histopathologic studies showed perivascular PAS-positive deposits. Biochemical studies confirmed the diagnosis of PCT.PCT should be included in the differential diagnosis of cutaneous hyperpigmentation in patients infected by human immunodeficiency virus (HIV).

The efficacy and tolerance of 7-chloro-3-[1-(2,4-dichlorophenyl)-2- (1H-imidazol-1-yl)ethoxy-methyl]benzo[b]thiophene (sertaconazole, FI-7045, CAS 99592-32-2) 2% dermatological cream in two daily applications compared with miconazole 2% cream in two daily applications were studied on 631 patients suffering from superficial cutaneous mycosis (sertaconazole n = 317, miconazole n = 314), in a double-blind, controlled multicentre trial with parallel groups. The therapeutic efficacy was evaluated by clinical assessment of the improvement of the lesion and symptoms, a microscopic test on the presence of hyphae or mycelia in the affected area and a culture test on the presence of active infection. Tolerance and safety were evaluated by a general blood analysis and interrogation of the patient on adverse effects. The rate of clinical cures for both treatments at the end of the follow-up was 95.6% for sertaconazole and 88.1% for miconazole, with the difference being statistically significant. In the comparative analysis of the actuarial curve, it was observed that the patients treated with sertaconazole were cured earlier and in a higher proportion than those treated with miconazole, with the difference being significant. The negative result of the microscope examination and culture test confirmed the superiority of sertaconazole over miconazole, already after 14 days of treatment. At the end of the follow-up, 98.6% of the patients in the sertaconazole group obtained a negative culture test result, as opposed to 91.7% in the miconazole group, with the difference being highly significant.(ABSTRACT TRUNCATED AT 250 WORDS)

7-Chloro-3-[1-(2,4-dichlorophenyl)-2-(1H-imidazol-1-yl)ethoxy-methyl] benzo[b]thiophene (sertaconazole, FI-7045, CAS 99592-32-2) is a new antimycotic which, in experimental infection studies, proved to possess potent antifungal activity. In a randomized, parallel, double-blind trial, the activity of sertaconazole cream was studied in 20 patients suffering from superficial mycoses caused by dermatophytes, confirmed by microscopic examination (KOH) and culture test. The patients, who were included in accordance with microbiological, microscopic and clinical criteria, were divided into two groups of 10 and were treated with sertaconazole 1% or sertaconazole 2% (cream) twice a day for 28 days. Both treatments achieved a total cure of the disease, with a cure being reached in a shorter time in the group of patients treated with sertaconazole 2%. No undesirable effects or statistically significant changes in the blood tests conducted at the end of the trial were observed. The results of the trial show that sertaconazole 2% cream is more effective. In view of the advantages offered by topical therapy over systemic therapy and of the good results obtained in patients with dermatophytosis, sertaconazole may represent an important advance in the therapy of superficial dermatophytoses.

The association between lichen planus (LP) and liver disease by the hepatitis C virus (HCV) has recently been described although its significance is controversial. The charts of 10 patients (8 women, 2 men) clinically and/or histologically diagnosed of LP and with positive HCV serology were retrospectively reviewed. Nine of the patients presented mucosal involvement, four of which were of the erosive form. In 7 patients liver disease preceded the appearance of LP. In the remaining 3 patients HCV infection was detected after the diagnosis of LP despite no alterations being observed in the liver function tests in 2 cases. Alpha-interferon 2b treatment triggered the lesions in 3 cases while leading to resolution of LP in another case. These data confirm the findings referred in the references and support the direct or indirect participation of HCV in LP.

The results of the study of 51 patients bearing a Milwaukee corset indicate that they present a mechanical and irritative dermatitis caused by the personal predisposition, the action of the plastic material and the occlusion and humidity produced between skin surface and the corset. The authors suggest the name Occlusive Dermatitis Syndrom for this cases as a subtype of Mechanical Irritative Dermatitis.

Wilms tumour and Acromelanosis is a rare association. The authors describe two white cases, and they believe is an accidental a association. However, it's possible that Acromelanosis was a paraneoplastic sign if the future carry most similar cases.

<h3>To the Editor.—</h3> Thymostimulin (TMS), a calf thymus extract, can be successfully used in the treatment of patients with viral diseases and cell-mediated immune defects. A significant reduction in the number of total circulating T lymphocytes has been observed in patients with psoriasis, while the number of circulating B cells was normal and there was an increase of null cells.¹In skin, the dermal mononuclear infiltrate consists almost exclusively of T lymphocytes and macrophages.² Recently, Baker et al³studied the relationship between T-cell populations in blood and in skin of psoriatic patients as well as the correlation with the chronicity, type, and extent of the skin lesions. In blood from patients with guttate psoriasis (GP), the reduction in the number of T lymphocytes was due entirely to a decrease in T helper-inducer (Th) cells. In chronic plaque (CP) psoriasis, both Th and suppressor-cytotoxic T-lymphocyte (Ts) subset were

After submitting a typical case of Anderson-Fabry disease in a 38 years old male, we discuss the eminent aspects of this metabolic disorder and, above all, the clinical, biochemical and ultrastructural problems of diagnosis in the heterozygotic relatives.